News Image

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

Provided By PR Newswire

Last update: Feb 12, 2025

Data shows that INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with clinical benefit as measured by reduced need for surgeries

Read more at prnewswire.com

INOVIO PHARMACEUTICALS INC

NASDAQ:INO (2/21/2025, 8:00:01 PM)

After market: 2.28 +0.04 (+1.79%)

2.24

+0.02 (+0.9%)



Find more stocks in the Stock Screener

Follow ChartMill for more